<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-138473</identifier>
<setSpec>0213-4853</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data</dc:title>
<dc:description xml:lang="en">Objective: This study aims to assess the response and safety of the treatment of multiple sclerosis (MS) episodes with high oral doses of methylprednisolone (MP) and to investigate the correlation between expanded disability status scale (EDSS) and MS functional composite (MSFC) during recovery from relapses. Method: Patients consecutively diagnosed of clinically defined MS with an episode of less than three weeks course were included. They were evaluated and treated with a single dose of 1,000 mg of MP for three days without oral tapering. Baseline EDSS and at least three MSFC scale measurements were available. Patients were scored with EDSS and MSFC before the treatment and after 1, 4 and 12 weeks. Adverse events were also recorded. Response to treatment was defined as the recovery of at least 1 point in the EDSS or the return to baseline EDSS. Results: Twenty one episodes in 20 patients were treated. Mean baseline EDSS was, 2.5; mean baseline z-score was, 0.15, and mean relapse duration was, 6.8 days. During relapse, mean EDSS worsened to 3.8 and mean z-score to -0.57. At week 1, 33.4% of relapses had responded to treatment, and at weeks 4 and 12, 85.7% had responded. Although mean EDSS and mean z-score had already improved at week 1, mean EDSS did not reach baseline value until week 4 and mean z-score until week 12. EDSS correlated significantly to MSFC in each evaluation as well as to scale changes related to relapse (p;0.05). No serious adverse events were seen. Discussion: Oral high-dose of MP is a safe and effective therapy for MS relapses. Both EDSS and MSFC were sensitive to changes related to relapses although the dynamics of recovery was different, providing complementary information (AU)</dc:description>
<dc:creator>Escutia, M</dc:creator>
<dc:creator>Coret, F</dc:creator>
<dc:creator>Casanova, B</dc:creator>
<dc:creator>Bernat, A</dc:creator>
<dc:creator>Boscá, I</dc:creator>
<dc:creator>Pascual, AM</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo. Evaluación de la respuesta y seguridad del tratamiento de brotes de esclerosis múltiple (EM) con dosis altas de metilprednisolona oral (MPO), y análisis de la correlación entre la escala de Kutzke (EDSS) y la escala funcional compuesta (EFC) en la evaluación de los cambios posbrote. Método. Se incluyeron consecutivamente pacientes diagnosticados de EM clínicamente definida con un brote de menos de 3 semanas de evolución. Los pacientes fueron evaluados y tratados con 1.000 mg de MPO en dosis única durante 3 días sin pauta de reducción. De todos disponíamos de una EDSS basal y al menos tres medidas de la EFC. Ambas escalas se completaron el día 0, antes del tratamiento, y las semanas 1, 4 y 12 después del mismo. Consideramos buena respuesta a la mejoría de al menos 1 punto en la EDSS respecto al día 0 o la recuperación de la EDSS basal. Resultados. Se trataron 21 brotes en 20 pacientes. EDSS basal media, 2,5; z-score de la EFC basal medio, 0,15; tiempo medio de evolución del brote, 6,8 días. Durante el brote la EDSS empeoró a 3,8 y el z-score a -0,57. Hubo buena respuesta en el 33,4 % de los brotes en la semana 1 y en el 85,7% en las semanas 4 y 12. Aunque ambas escalas mejoraron significativamente en la primera semana, la EDSS media no recuperó su valor basal hasta la semana 4 y la EFC lo hizo en la semana 12. Las escalas se correlacionaron en cada evaluación y respecto a los cambios debidos al brote (p&lt;0,01). No se registraron acontecimientos adversos graves. Discusión. La megadosis de MPO es un tratamiento seguro y eficaz de los brotes de EM. EDSS y EFC son sensibles a los cambios posbrote, aunque su dinámica de recuperación es diferente, proporcionándonos cada una información complementaria (AU)</dc:description>
<dc:source>Neurologia;23(2): 73-77, mar. 2008. tab</dc:source>
<dc:identifier>ibc-138473</dc:identifier>
<dc:title xml:lang="es">Evaluación prospectiva del tratamiento de brotes de sclerosis múltiple con megadosis oral de metilprednisolona: datos de respuesta y seguridad</dc:title>
<dc:subject>^d9296^s22057</dc:subject>
<dc:subject>^d29623</dc:subject>
<dc:subject>^d4245</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d6082^s22020</dc:subject>
<dc:subject>^d22562^s22000</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d6082^s22073</dc:subject>
<dc:subject>^d12428</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d22562^s22073</dc:subject>
<dc:subject>^d6082^s22000</dc:subject>
<dc:subject>^d22562^s22020</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d9296^s22054</dc:subject>
<dc:subject>^d9296^s22032</dc:subject>
<dc:subject>^d18001</dc:subject>
<dc:type>article</dc:type>
<dc:date>200803</dc:date>
</metadata>
</record>
</ibecs-document>
